However, prolonged progression-free survival appears correlated with a high angiogenin level (≥330 ng/mL), which might therefore be predictive of the clinical outcome in patients with early-stage CLL [87] (Table 1). This evidence concerns the gene ANG and B-cell chronic lymphocytic leukemia.